Description:

Background

Nanotherapeutics were developed to improve the safety and efficacy of anticancer drugs. However, as the targeting was solely based on enhanced permeability and retention effect exhibited by the cancer cells, there were many offsite effects observed. 

Liposomes are nanoparticles comprised of a self-assembled lipid bilayer encapsulating an aqueous core. Dual functionalization of the liposome with antibodies or peptides can result in the antagonism of the cell receptors which results in immune suppression. Dual functionalization liposomes can cooperatively bind multiple receptors leading to significant changes in gene suppression. 

Next-generation tumor-targeting ligands improved tumor accumulation but offsite adverse effects still persist. 

Technology Overview

To overcome these problems, researchers have functionalized the surface of the liposomes to precisely complement the molecular ratio and organization of multiple cancer receptors overexpressed on cancerous cells. 

Researchers have synthesized liposomes with aqueous core with a dual functionalized surface. Dual functionalization of the liposome with antibodies or peptides with affinity to programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), or programmed death 1 (PD-1) results in the antagonism of cell receptors which result in immune suppression. Theses dual functionalized liposomes can cooperatively bind multiple receptors leading to significant changes in gene expression and anti-tumor activity. 

Benefits

  • Strong adhesion 
  • Increased cell binding and altering gene expression 
  • Can bind two receptors on one cell surface 
  • Peptides are cheaper and may exhibit reduced immunogenicity 
  • Synergistic effect as multiple gene expressions have been altered 
  • Activation of anti-tumor response by the immune system 
  • Reduced metastasis 
  • Reduced immunogenicity against the liposomes 

Applications

  • Immunotherapy efficacy 
  • Cancer therapy by reduced tumor burden and metastasis 
Patent Information:
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
m.saulich@northeastern.edu
Inventors:
Debra Auguste
Keywords:
Biomaterials
Cancer
Drug Delivery